A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

Table 2

(a) Patient baseline characteristics (intention-to-treat population)

		Control	Group A	Group B	p value
Age; (years)	n	33	33	34	p=0.34
	Mean±SD	61.4±7.1	58.2±8.9	60.1±9.5
	Min-Max	48-80	35-78	38-76
BMI	n	33	33	34	p=0.84
	Mean±SD	22.9±2.7	23.1±2.0	23.1±2.9
	Median	22.6	23.1	22.6
WOMAC; total score	n	33	33	34	p=0.99
	Mean±SD	44.9±15.2	44.4±16.2	45.2±13.1
	Median	48	47	42
Sex
Male	n	2	3	3	p=0.9
	%	6.1	9.1	8.8
Female	n	31	30	31
	%	93.9	90.9	91.2

: Kruskal-Wallis test. : Fisher exact test

(b) Patient baseline characteristics (per-protocol population)

		Control	Group A	Group B	p value
Age; (years)	n	24	31	27	p=0.06
	Mean±SD	62.8±7.6	60.3±8.8	59.6±8.8
	Min-Max	48-80	40-76	35-78
BMI	n	24	31	27	p=0.66
	Mean±SD	23.2±2.7	23.1±2.0	22.9±2.5
	Median	23.0	23.1	22.6
WOMAC; total score	n	24	31	27	p=0.88
	Mean±SD	43.4±15.3	43.9±15.9	46.0±13.4
	Median	47	46	45
Sex
Male	n	2	2	3	p=0.89
	%	8.33	6.45	11.11
Female	n	22	29	24
	%	91.67	93.55	88.89

: Kruskal-Wallis test. : Fisher exact test